the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
Published 1 year ago • 128 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
0:46
the role of pacritinib in managing thrombocytopenia in patients with myelofibrosis
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
3:05
ruxolitinib, pacritinib, fedratinib or momelotinib for thrombocytopenic patients with myelofibrosis
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
1:15
potential approval of pacritinib for the treatment of myelofibrosis
-
1:24
the promising role of pacritinib for the treatment of patients with mf and severe thrombocytopenia
-
21:38
drawing the line: the rationale behind blood tube collection order
-
1:06:04
itp: novel treatments
-
5:13
what is itp? | symptoms and causes of itp | why october is itp awareness month? | therrapie
-
1:36
the impact of tp53 mutations in patients with myelofibrosis undergoing sct
-
2:28
investigating the impact of pacritinib on survival in patients with mf and severe thrombocytopenia
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
3:11
the therapeutic implications of shared pathophysiology in classical itp and other thrombocytopenias
-
4:48
an insight into the management of cytopenias in mf
-
1:16
using rwd to evaluate the use of fedratinib as a potential bridge to hsct in patients with mf
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks